Introduction to Midd Training Module 2 Part Two
Let's dive into the details surrounding Midd Training Module 2 Part Two. Stacy Tannenbaum, the lead of the Pharmacometrics Group in the US for Astellas Pharma Global Development, discusses ...
Midd Training Module 2 Part Two Comprehensive Overview
Stacy Tannenbaum, lead of the Pharmacometrics Group in the US for Astellas Pharma Global Development, reviews the various ... This lecture by Dr. Rajesh Krishna is a case study showing how anti-viral kinetic modeling can be used to support drug ... This lecture by Drs. Adekemi, Taylor, Rajesh Krishna and S.Y. Amy Cheung, Senior Directors of Integrated Drug Development at ...
Dr. Qi Liu, the Assoc. Director for Innovation & Partnership in the Office of Clinical Pharmacology, Office of Translational Sciences ...
Summary & Highlights for Midd Training Module 2 Part Two
- Jeffrey Barrett from the Critical Path Institute provides the overview of this
- This lecture by Jeffrey Barrett from the Critical Path Institute describes the
- Dr. Mark R. Gasronguay, Founder and CEO of the Metrum Research Group, discusses how to use simulation from a mathematical ...
- Clinical Pharmacologist Dr. Colin Pillai discusses if there are differences between an industry versus a regulatory setting, or if ...
- This lecture is
That wraps up our extensive overview of Midd Training Module 2 Part Two.